Gilead Sciences: Failed Trial Always a ‘Long Shot’

Yesterday, RBC defended Gilead Sciences (GILD) after the failure of a drug trial for simtuzumab patients with pancreatic cancer. Today, Maxim’s Jason Kolbert leaps in to argue that the trial was always a “long shot.” He explains why: We have always felt that an indication for the treatment of pancreatic cancer (PC) represents “a very [...]